Related Experiment Video
Updated: Jun 27, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
From angiotensin IV binding site to AT4 receptor
1Department of Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, Brussels, Belgium. pvandhey@vub.ac.be
Molecular and Cellular Endocrinology
|December 17, 2008
Summary
Angiotensin IV (Ang IV), a cardiovascular hormone fragment, exhibits distinct biological effects mediated by the AT4 receptor, identified as insulin-regulated aminopeptidase (IRAP). This research explores Ang IV
Area of Science:
- Cardiovascular endocrinology
- Receptor pharmacology
- Cellular signaling
Background:
- Angiotensin II (Ang II) has fragments with significant biological activity.
- Angiotensin IV (Ang IV), a specific Ang II fragment, elicits effects not explained by AT1/AT2 receptors.
- High-affinity Ang IV binding sites suggested a novel AT4 receptor.
Purpose of the Study:
- To define the AT4 receptor and its associated biological functions.
- To link Ang IV binding to cellular signaling pathways.
- To investigate the cellular effects of AT4 ligands.
Main Methods:
- Characterization of high-affinity [(125)I]-Ang IV binding sites.
- Identification of the AT4 receptor as insulin-regulated aminopeptidase (IRAP).
- Utilizing cultured cells to study ligand-induced signaling.
Main Results:
- The AT4 receptor was identified as IRAP.
- Distinct tissue distribution of Ang IV binding sites was observed.
- Cultured cells demonstrated the link between AT4 receptor binding and cellular effects.
Conclusions:
- Angiotensin IV (Ang IV) exerts biological effects via the AT4 receptor, identified as IRAP.
- The AT4 receptor plays a role in cellular processes linked to Ang IV.
- Further research into AT4 receptor signaling is warranted.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...